- About
- Organization
- Organization Overview
- Dean’s Office
- Department of Bioengineering and Therapeutic Sciences
- Department of Clinical Pharmacy
- Department of Pharmaceutical Chemistry
- Quantitative Biosciences Institute
- Org Chart
- Research
- Education
- Patient Care
- People
- News
- Events
Phillips discusses insurance coverage for genomic testing
By UCSF School of Pharmacy Editorial Staff / Tue Apr 24, 2018
Kathryn Phillips, PhD, discusses insurance coverage for genomic testing in her recent articles published in JAMA and Science.
In a JAMA Viewpoint, April 16, Phillips examines the new CMS coverage policy for genomic tests in cancer patients: “Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning?”
In a letter in Science, April 20, she considers: “Insurance coverage for genomic tests.”
Phillips is a faculty member in the Department of Clinical Pharmacy. She is a health services and policy researcher and health economist, and the founding director of the TRANSPERS Center (Center for Translational and Policy Research on Personalized Medicine).
Tags
Topics:
Category:
Sites:
Department of Clinical Pharmacy
Related profiles
About the School: The UCSF School of Pharmacy aims to solve the most pressing health care problems and strives to ensure that each patient receives the safest, most effective treatments. Our discoveries seed the development of novel therapies, and our researchers consistently lead the nation in NIH funding. The School’s doctor of pharmacy (PharmD) degree program, with its unique emphasis on scientific thinking, prepares students to be critical thinkers and leaders in their field.
Related news
- Research outlines challenges for adoption of new genetic tests
- Phillips leads national study of benefit/risk in emergent whole genome sequencing
- TRANSPERS and UCSF Precision Medicine join forces with Access and Value Program
- Phillips named as Member of National Academy of Medicine Roundtable on Genomics and Precision Health
- Study identifies lack of information about HER2 testing practices
